Startseite>>Isotope-Labeled Compounds>> Deuterium>>MAM2201 N-(5-chloropentyl) analog-d5

MAM2201 N-(5-chloropentyl) analog-d5 (Synonyms: JWH 122 N(5chloropentyl) analogd5)

Katalog-Nr.GC47593

A neuropeptide with diverse biological activities

Products are for research use only. Not for human use. We do not sell to patients.

MAM2201 N-(5-chloropentyl) analog-d5 Chemische Struktur

Cas No.: 2748212-99-7

Größe Preis Lagerbestand Menge
500 μg
111,00 $
Auf Lager
1 mg
213,00 $
Auf Lager
5 mg
891,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

MAM2201 N-(5-chloropentyl) analog-d5 contains five deuterium atoms at the 2, 4, 5, 6, and 7 positions. It is intended for use as an internal standard for the quantification of MAM2201 N-(5-chloropentyl) analog by GC- or LC-mass spectrometry. MAM2201 is a synthetic cannabinoid (CB) that is closely related, structurally, to AM2201 , a compound which displays high affinities for both CB receptors.1 MAM2201 N-(5-chloropentyl) analog differs from MAM2201 by having chlorine rather than fluorine on the terminal carbon of the alkyl group. The physiological properties of this compound have not been evaluated. This product is intended for forensic and research applications.

1.Makriyannis, A., and Deng, H.Cannabimimetic indole derivativesPCT/US00/28832(2001)

Bewertungen

Review for MAM2201 N-(5-chloropentyl) analog-d5

Average Rating: 5 ★★★★★ (Based on Reviews and 38 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for MAM2201 N-(5-chloropentyl) analog-d5

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.